About Formosa Pharmaceuticals

Company Introduction

Formosa Pharmaceuticals, a subsidiary of globally-recognized API and CDMO provider, Formosa Laboratories (TWSE 4746), is a late-preclinical and early-clinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.

In August, 2017, Formosa Pharmaceuticals acquired Activus Pharmaceuticals (Funabashi, Japan), which afforded Formosa Pharmaceuticals a proprietary nanoparticle technology platform (APNT), and two late-stage preclinical assets in ophthalmology. Of these ophthalmology candidates, APP13007 has just begun Phase 3 clinical trials in the United States for inflammation and pain after ocular surgery.

Collaborating with global strategic partners, Formosa Pharmaceuticals has assembled a unique pipeline of diverse assets. Each opportunity has a different risk profile and enjoys a unique advantage with respect to the company’s resources, infrastructure, and network.

Formosa Pharmaceuticals continues to seek additional valued partnerships to complement its existing pipeline and platform technologies.

Development Pipeline

Scroll to Top